Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

gargoyl Aug. 25 at 1:10 PM

$XBI with the 50 crossover 200 around $90 and higher lows from May 22 the chart looking for a continuation uptrend along side risk on Bio. This week, with a perfect storm all ships rise with incoming tide .. $BLRX 👀 for the $4.50 pop

0 · Reply

gargoyl Aug. 22 at 7:51 PM

$BLRX Just put aside some cold fresh brew coffee, something’s in life take time , hear 👂 is to the few longs 🫴🍷 , and to the looser short nay sayers 🤌 time to change sides .. have you noticed one of your leaders have already. Phil has cash, Phil has residual income revenue, Phil has PDAC, SCD, MM cards.. Not to mention 4 collaborations with respected Universities and entities , ie. St Jude.. Phil welcomes the haters as every brave investment that requires fortitude has the overnighters and miss informed untimely traders. One remedy, average in.

0 · Reply

gargoyl Aug. 22 at 5:15 PM

$BLRX look 👀 Extremely Bullish Foundation set, cash on hand runway till 2027 28M double current valuation, little expenses , Watch the 🪳 scurry when the 💡 pops Phil is in the final hand 🏆 Longest the 🦋

0 · Reply

DiaJay Aug. 22 at 3:28 PM

$BLRX it should continuously be stated that this company lost 96% of its value in the last five years. It has no path to profitability. It has no upcoming catalysts. The CEO works hand in hand with the company that rates BLRX and handles the stock dilution. Revenue does not even pay the CEO’s salary. Several conversations ago it was discussed that the investment losers in this stock need to suck it up and move on. There is a whole new crop of suckers to fleece in the upcoming year. I only wish just one person would have spoken out that the business model here is only to fleece the shareholders. It is sad but those are the facts.

0 · Reply

gargoyl Aug. 21 at 11:25 AM

$BLRX 4 of 4

0 · Reply

gargoyl Aug. 21 at 11:24 AM

$BLRX 3 of 4

0 · Reply

gargoyl Aug. 21 at 11:24 AM

$BLRX 2 of 4

0 · Reply

gargoyl Aug. 21 at 11:23 AM

$BLRX 👀 1 of 4 Updated Website, go to company’s website

0 · Reply

GreedyBastard4Ever Aug. 20 at 7:05 AM

$BLRX facts. Buy

0 · Reply

tankwfwf Aug. 19 at 7:36 PM

$BLRX Phil wants it on credit. LOL............

0 · Reply

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:00 AM EDT - 11 days ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 18 days ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

May 30, 2025, 1:58 PM EDT - 3 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 7:00 AM EDT - 3 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 27, 2025, 12:55 PM EDT - 3 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 7:00 AM EDT - 3 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 20, 2025, 7:00 AM EDT - 3 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Mar 31, 2025, 10:52 AM EDT - 5 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:00 AM EDT - 5 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:00 AM EDT - 5 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Jan 21, 2025, 7:00 AM EST - 7 months ago

BioLineRx Issues Letter to Shareholders

Jan 17, 2025, 7:00 AM EST - 7 months ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 6, 2025, 2:01 PM EST - 8 months ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 8:57 AM EST - 8 months ago

BioLineRx Announces $10 Million Registered Direct Offering

Nov 25, 2024, 10:58 AM EST - 9 months ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 7:00 AM EST - 9 months ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 21, 2024, 6:30 AM EST - 9 months ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 9 months ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 10 months ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 11 months ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Aug 15, 2024, 3:03 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 1 year ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 11:38 AM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 1 year ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 4, 2023, 6:42 PM EST - 1 year ago

BioLineRx: Still A Buy, With Some Questions

Dec 2, 2023, 11:25 PM EST - 1 year ago

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges

Nov 20, 2023, 1:54 PM EST - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript

Nov 20, 2023, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Nov 13, 2023, 7:00 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Oct 31, 2023, 9:00 AM EDT - 1 year ago

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Oct 12, 2023, 7:00 AM EDT - 2 years ago

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

gargoyl Aug. 25 at 1:10 PM

0 · Reply

gargoyl Aug. 22 at 7:51 PM

0 · Reply

gargoyl Aug. 22 at 5:15 PM

0 · Reply

DiaJay Aug. 22 at 3:28 PM

0 · Reply

gargoyl Aug. 21 at 11:25 AM

$BLRX 4 of 4

0 · Reply

gargoyl Aug. 21 at 11:24 AM

$BLRX 3 of 4

0 · Reply

gargoyl Aug. 21 at 11:24 AM

$BLRX 2 of 4

0 · Reply

gargoyl Aug. 21 at 11:23 AM

$BLRX 👀 1 of 4 Updated Website, go to company’s website

0 · Reply

GreedyBastard4Ever Aug. 20 at 7:05 AM

$BLRX facts. Buy

0 · Reply

tankwfwf Aug. 19 at 7:36 PM

$BLRX Phil wants it on credit. LOL............

0 · Reply

gargoyl Aug. 19 at 5:50 PM

$BLRX MM can’t confine this under $4 anymore , his book is spread open wide , like the 3.66 - 3.87 Bid Ask. 47k shares traded as of now…. Watching this closely for the pop. A little volume pressure we run. 🏃‍♀️

0 · Reply

gargoyl Aug. 19 at 4:55 PM

$BLRX 👀 averaging in yet again. - The foundation is in. - No more dilution , company has 28M cash runaway for two years till 2027. - PDAC alone can make this stonk a a 10x bagger 🏆 - Pipeline is on the backs of 3 or 4 collaborating Universities ( Phil brilliant) - Expenses are next to nothing till they grab another asset this year as per reported in recent 2Q ER. - Two partners already ramping up revenues and potential catalysts. - liking the risk reward hear 👂 - Bio pharma is back risk on - small 🧢 caps are back - most important, notice the cockroaches 🪳 crawling out again .. Watch , do DD this 💎 goes beast mode 🦍 Longest the 🦋

0 · Reply

AfghanBattleRat Aug. 19 at 3:55 AM

$BLRX

0 · Reply

BlakeTaylor12 Aug. 18 at 10:43 PM

$BLRX I'm alive! Miss me? I think I bought 50 shares today. First time I've bought in well over a year..maybe 2. Going to slowly average down but when they dilute I intend on going in pretty big. I'm trying to understand how a c company with zero money wants to buy an asset 🤦‍♂️🤦‍♂️

1 · Reply

gargoyl Aug. 18 at 3:00 PM

$BLRX 👀 very bullish here, 👂. The last PDAC data on top of existing pipeline and collaborations , not to mention her two partners (but mentioning it) Gloria and Arymid revenues and 🐈‍⬛ alysts, the current Macro and Micro risk on for bio , the competitions failed trials in SCD , MM and PDAC keeping us in race for last one standing brings risk reward in line for value and growth investors. 28M in cash for a 2027 run with little expenses due to debt pay down make Phil the foundation builder to continued success w/ past commercialization and now an eye on a new asset for 2025 to boot. 👢 Got to go , my brother entered the room, he’s 13, he’s gifted, sees things , algos , movements in price action not easily detected, he says we pop. 🦍 👀 Ignore the fear loosing negative resentment short posts .. Long the 🦋

0 · Reply

tankwfwf Aug. 16 at 5:05 PM

$BLRX Phil's searching for a sweet spot he says. You can bet the spot will be another enterprise that favors his cronies and will be praised by HC Wainwright and cost the shareholders. He is a liar and his BOD are complicit as well. What did he do to piss Gloria off ????????????

0 · Reply

ZacksSCR Aug. 15 at 7:59 PM

$BLRX: ASCO Poster & Abstract https://buff.ly/IIA6ZdS

0 · Reply

gargoyl Aug. 15 at 2:23 PM

$BLRX here’s a good match , cancer - tumor- immunology- unmet needs - opportunity 🤔

0 · Reply

TwongStocks Aug. 15 at 1:50 PM

$BLRX Also want to add. Phil said that Columbia University has the right to publish the CHEMO4METPANC data first. Which means we will likely see the interim data be released at a medical conference before the company can PR it. Columbia has previously presented CHEMO4METPANC data at AACR and ASCO. Some 2026 Conference dates: • ASCO GI Symposium Jan 8-10 2026. Submission deadline is Sept 2025 and Late breaking submissions due Oct 2025. Probably too early to submit here, not sure if they will reach 40% interim analysis by the submission deadlines. • AACR Apr 17-26 2026. Nov 2025 abstarct submission deadline, Jan 7 deadline for late breaking abstracts. Again, not sure if they will have interim analysis ready for submission here. The following conferences do not have abstract submission details available yet: • ASCO May 29-Jun 2 2026. • ESMO GI Cancers Congress 1-4 July 2026 • ESMO Congress 23-27 Oct 2026 • SITC 4-8 Nov 2026

1 · Reply

TwongStocks Aug. 15 at 1:19 PM

$BLRX Transcript available here. https://www.insidermonkey.com/blog/biolinerx-ltd-nasdaqblrx-q2-2025-earnings-call-transcript-1591168/ The prepared remarks are mostly similar in messaging to what Phil has stated in previous calls. Some highlights from the Q&A. A few pieces of information that haven't really been disclosed previously: • With regard to CHEMO4METPANC, Phil confirmed that Regeneron does not have any options or rights of first refusal. • They confirmed that the CHEMO4METPANC interim analysis will likely not lead to an accelerated approval. 40% events in a 100 patient study wil likely not be a sufficient sample size. And the primary endpoint is PFS. The standard primary endpoint for PDAC is OS. • With regard to pipeline expansion, they are targeting closing a transaction by EoY. Looking for early stage assets (IND to Phase 1). Looking for assets that are affordable, something without a large upfront payment. They are confident that their experience bringing motixafirtide to approval gives them a leg up in negotiations.

0 · Reply

TwongStocks Aug. 14 at 8:16 PM

$BLRX Highbridge amended their 13G https://www.sec.gov/Archives/edgar/data/919185/000090266425003619/xslSCHEDULE_13G_X01/primary_doc.xml Beneficial ownership is now 7.2%. They now own 288,251 ADS in the form of warrants: "The 172,950,600 Ordinary Shares (as defined in Item 2(a)) reported herein are represented by 288,251 ADSs (as defined in Item 2(a)) issuable upon exercise of warrants." Recall that when BLRX sold their Aphexda rights to Ayrmid, Highbridge made a $9M equity investment in BLRX (screenshot).

0 · Reply

gargoyl Aug. 14 at 7:06 PM

$BLRX lol, MM book is so thin and spread open , he can’t even organize a shake out , watch this now , after an ER BLRX is almost even , don’t quit your day job over this but it deserves the other side of the deal it’s been delt for past 10 years .. wow this guy is a fighter, he’s not giving up , respect ✊

0 · Reply

Market Cap	15.94M
Revenue (ttm)	28.94M
Net Income (ttm)	-9.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-31.86%
Debt to Equity Ratio	0.56

Volume	51,300
Avg Vol	52,780
Day's Range	N/A - N/A
Shares Out	4.26M
Stochastic %K	53%
Beta	1.15
Analysts	Strong Sell
Price Target	$26.00